BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis - review

Memórias do Instituto Oswaldo Cruz

Thereza Christina Benévolo-de-andrade²  Renata Monteiro-maia¹  Catherine Cosgrove¹  Luiz Roberto R Castello-branco² 

[1] ,Fiocruz Instituto Oswaldo Cruz Departamento de ImunologiaRio de Janeiro RJ ,Brasil

关键词: BCG Moreau Rio de Janeiro;    oral vaccine;    review;   

DOI  :  10.1590/S0074-02762005000500002

来源: SciELO

【 摘 要 】

The vaccine Bacillus of Calmette Guérin (BCG) was originally developed in France as an oral vaccine against tuberculosis. The oral use of this vaccine was replaced by the parenteral route in almost all countries after the Lubeck disaster. In contrast, Brazil retained the oral delivery of the vaccine until the mid-seventies when it was replaced by the intradermal route. This change in route of delivery was mainly secondary to pressure by medical practitioners based on the poor responses of oral immunized subjects to purified protein derivative (PPD) skin tests. Even after the change of route of delivery, Ataulpho de Paiva Foundation continued making the oral vaccine. Currently, BCG Moreau has been described as one of the most immunogenic and with fewer side effects than other BCGs. The genomics, proteomics and vaccine trials for oral BCG Moreau Rio de Janeiro are currently under investigation. In this review, we intend to describe the history of BCG Moreau Rio de Janeiro in Brazil.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License